A noninvasive method to measure splanchnic glucose uptake after oral glucose administration.

B Ludvik; J J Nolan; A Roberts; J Baloga; M Joyce; J M Bell; J M Olefsky

doi:10.1172/JCI117913

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Ludvik, B. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Nolan, J. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Roberts, A. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Baloga, J. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Joyce, M. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Bell, J. in: PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093, USA.

Find articles by Olefsky, J. in: PubMed | Google Scholar

Published in Volume 95, Issue 5 on May 1, 1995
J Clin Invest. 1995;95(5):2232–2238. https://doi.org/10.1172/JCI117913.
© 1995 The American Society for Clinical Investigation

Published May 1, 1995 - Version history

We have developed a noninvasive method to estimate splanchnic glucose uptake (SGU) in humans (oral glucose clamp technique [OG-CLAMP]), which combines a hyperinsulinemic clamp with an oral glucose load (oral glucose tolerance test). We validated this method in 12 nondiabetic subjects using hepatic vein catheterization (HVC) during an oral glucose tolerance test. During HVC, splanchnic blood flow increased from 1,395 +/- 64 to 1,935 +/- 109 ml/min, returning to basal after 180 min and accounted for 45 +/- 7% of SGU in lean and 19 +/- 5% in obese subjects (P < 0.05). SGU estimated during the OG-CLAMP was 22 +/- 2% of the glucose load, and this was significantly correlated (r = 0.90, P < 0.0001) with SGU (35 +/- 4%) and with first pass SGU (24 +/- 3%; r = 0.83, P < 0.001) measured during HVC. SGU was higher in obese than in lean subjects during OG-CLAMP (27 +/- 1% vs 18 +/- 3%, P < 0.01) and HVC (44 +/- 4% vs 26 +/- 5%, P < 0.05). In conclusion, SGU during the OG-CLAMP is well correlated to SGU measured during HVC. An increase in splanchnic blood flow is a major contributor to SGU in lean subjects. SGU is increased in obese subjects as measured by both methods.